JP2012530758A - 新規化合物、医薬組成物及びそれに関する方法 - Google Patents

新規化合物、医薬組成物及びそれに関する方法 Download PDF

Info

Publication number
JP2012530758A
JP2012530758A JP2012516707A JP2012516707A JP2012530758A JP 2012530758 A JP2012530758 A JP 2012530758A JP 2012516707 A JP2012516707 A JP 2012516707A JP 2012516707 A JP2012516707 A JP 2012516707A JP 2012530758 A JP2012530758 A JP 2012530758A
Authority
JP
Japan
Prior art keywords
alkyl
independently
alk
aryl
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012516707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530758A5 (OSRAM
Inventor
トラン，ジョー・エイ
チェン，チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of JP2012530758A publication Critical patent/JP2012530758A/ja
Publication of JP2012530758A5 publication Critical patent/JP2012530758A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012516707A 2009-06-24 2010-06-23 新規化合物、医薬組成物及びそれに関する方法 Pending JP2012530758A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22012509P 2009-06-24 2009-06-24
US61/220,125 2009-06-24
PCT/EP2010/058874 WO2010149685A1 (en) 2009-06-24 2010-06-23 New compounds, pharmaceutical composition and methods relating thereto

Publications (2)

Publication Number Publication Date
JP2012530758A true JP2012530758A (ja) 2012-12-06
JP2012530758A5 JP2012530758A5 (OSRAM) 2013-08-08

Family

ID=42712012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012516707A Pending JP2012530758A (ja) 2009-06-24 2010-06-23 新規化合物、医薬組成物及びそれに関する方法

Country Status (6)

Country Link
US (1) US8481731B2 (OSRAM)
EP (1) EP2445901A1 (OSRAM)
JP (1) JP2012530758A (OSRAM)
AR (1) AR077214A1 (OSRAM)
TW (1) TW201113269A (OSRAM)
WO (1) WO2010149685A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519253A (ja) * 2015-04-29 2018-07-19 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ５２に関連する障害の治療または予防に有用なｇｐｒ５２のモジュレーターとしての１−ヘテロアリール−インドリン−４−カルボキサミド

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399914A4 (en) * 2009-02-18 2012-08-29 Takeda Pharmaceutical FUSED HETEROCYCLIC CORE COMPOUND
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
AU2012208530A1 (en) 2011-01-21 2013-07-11 Boehringer Ingelheim International Gmbh Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders
JP5935154B2 (ja) 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
US8921398B2 (en) 2011-06-09 2014-12-30 Boehringer Ingelheim International Gmbh N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions and uses thereof
TWI682707B (zh) * 2017-02-24 2020-01-11 緯創資通股份有限公司 組裝組件及其組裝方法
CN116655598B (zh) * 2023-01-11 2025-04-25 黑龙江中医药大学 一种用于降血糖的药物及其制备方法
WO2024258988A2 (en) * 2023-06-13 2024-12-19 Delix Therapeutics, Inc. Serotonin releasing compounds and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528856A (ja) * 2003-07-11 2007-10-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての三置換アリールおよびヘテロアリール誘導体ならびにそれらに関連する障害の予防および治療
WO2008008887A2 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for treating metabolic disorders
WO2009051119A1 (ja) * 2007-10-16 2009-04-23 Daiichi Sankyo Company, Limited ピリミジルインドリン化合物
WO2010095663A1 (ja) * 2009-02-18 2010-08-26 武田薬品工業株式会社 縮合複素環化合物
WO2010119881A1 (ja) * 2009-04-15 2010-10-21 第一三共株式会社 インドリン化合物
JP2010265258A (ja) * 2009-04-15 2010-11-25 Daiichi Sankyo Co Ltd ピリミジルインドリン化合物を含有する医薬組成物
JP2012526097A (ja) * 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
JP2012526096A (ja) * 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
WO2002102783A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
DE602004009295T2 (de) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
US7083933B1 (en) * 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
CN1898235A (zh) 2003-12-24 2007-01-17 普罗西迪恩有限公司 作为gpcr受体激动剂的杂环衍生物
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
BRPI0516407A (pt) 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20080249091A1 (en) 2005-01-19 2008-10-09 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
US20100197687A1 (en) 2005-01-19 2010-08-05 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
EP1838669A1 (en) 2005-01-19 2007-10-03 Biolipox AB Indoles useful in the treatment of inflammation
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
DE602006006461D1 (de) 2005-09-16 2009-06-04 Arena Pharm Inc Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
MX2008011661A (es) 2006-03-16 2008-09-22 Novartis Ag Compuestos organicos heterociclicos para el tratamiento de melanoma en particular.
BRPI0710839A2 (pt) 2006-04-06 2011-08-23 Prosidion Ltd agonistas heterocìclicos de gpcr
AU2007238805B2 (en) 2006-04-11 2012-04-05 Arena Pharmaceuticals, Inc. Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
WO2008009924A2 (en) 2006-07-18 2008-01-24 Biolipox Ab Indoles useful in the treatment of inflammation
EP2059516A1 (en) 2006-08-30 2009-05-20 BIOVITRUM AB (publ) Pyridine compounds for treating gpr119 related disorders
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
SI2114933T1 (sl) 2007-01-04 2012-01-31 Prosidion Ltd Windrush Court Piperidinski gpcr-agonisti
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
JP2010514832A (ja) 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンｇｐｃｒアゴニスト
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
BRPI0808775A2 (pt) 2007-03-08 2017-05-30 Irm Llc compostos e composições como moduladores de atividade de gpr119
BRPI0809542A8 (pt) 2007-03-29 2015-09-15 Asubio Pharma Co Ltd Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
CN101668759A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,5]-双环gpr119g蛋白-偶合受体激动剂
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
TW200904440A (en) 2007-07-17 2009-02-01 Bristol Myers Squibb Co Method for modulating GPR119 G protein-coupled receptor and selected compounds
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
EP2197873B1 (en) 2007-09-20 2014-07-16 Irm Llc Compounds and compositions as modulators of gpr119 activity
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2224928A4 (en) 2007-12-06 2012-02-15 Glaxosmithkline Llc NOVEL INHIBITORS OF SEH AND THEIR USE
EA201001329A1 (ru) 2008-02-22 2011-04-29 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
CA2714703A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
DK2280704T3 (en) 2008-03-31 2015-06-29 Cymabay Therapeutics Inc Oxymethylenarylforbindelser and uses thereof
KR20110002465A (ko) 2008-03-31 2011-01-07 젠야쿠코교가부시키가이샤 세포 보호 작용을 갖는 피리미딘 유도체 및 그 용도
EP2271619A1 (en) 2008-04-07 2011-01-12 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009125434A2 (en) 2008-04-07 2009-10-15 Cadila Healthcare Limited Oxime derivatives
US8343990B2 (en) 2008-04-14 2013-01-01 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
JP2011527332A (ja) 2008-07-10 2011-10-27 プロシディオン・リミテッド ピペリジンｇｐｃｒ作動薬
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812642D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
PE20110329A1 (es) 2008-07-10 2011-06-03 Prosidion Ltd Agonistas del receptor acoplado a la proteina g piperidinilo
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
BRPI0915867A2 (pt) 2008-07-11 2017-06-20 Irm Llc 4-fenoximetilpiperidinas como moduladores de atividade de gpr119
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
WO2010014593A1 (en) 2008-07-30 2010-02-04 Smithkline Beecham Corporation Chemical compounds and uses
EP2311822A4 (en) 2008-08-01 2011-08-31 Nippon Chemiphar Co GPR119 AGONIST
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010059385A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidne derivatives useful as gdir agonists
US20100113479A1 (en) * 2008-10-30 2010-05-06 Anusuya Choudhury Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
JP2012513469A (ja) 2008-12-23 2012-06-14 シェーリング コーポレイション ピリミジン誘導体及びその使用法
US8410122B2 (en) 2008-12-23 2013-04-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
EP2379542B1 (en) 2008-12-24 2013-02-13 Cadila Healthcare Limited Novel oxime derivatives
WO2010074271A1 (ja) 2008-12-26 2010-07-01 武田薬品工業株式会社 糖尿病治療剤
WO2010084944A1 (ja) 2009-01-22 2010-07-29 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
JP2012136439A (ja) 2009-04-24 2012-07-19 Nippon Chemiphar Co Ltd ジアザスピロアルカン誘導体
US20100285145A1 (en) * 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
WO2010135505A2 (en) 2009-05-20 2010-11-25 Janssen Pharmaceutica Nv Crystalline forms of 4-[6-(6-methanesulfonyl-2-methylpyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
US20100298362A1 (en) 2009-05-20 2010-11-25 Xun Li Process for the preparation of 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EA201200046A1 (ru) * 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
US8772323B2 (en) 2010-05-07 2014-07-08 Boehringer Ingelheim International Gmbh Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
AU2012208530A1 (en) 2011-01-21 2013-07-11 Boehringer Ingelheim International Gmbh Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders
JP5935154B2 (ja) 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528856A (ja) * 2003-07-11 2007-10-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての三置換アリールおよびヘテロアリール誘導体ならびにそれらに関連する障害の予防および治療
WO2008008887A2 (en) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Gpr119 agonists for treating metabolic disorders
JP2009543805A (ja) * 2006-07-13 2009-12-10 スミスクライン ビーチャム コーポレーション インドリン誘導体及びｇｐｒ１１９作動物質
WO2009051119A1 (ja) * 2007-10-16 2009-04-23 Daiichi Sankyo Company, Limited ピリミジルインドリン化合物
WO2010095663A1 (ja) * 2009-02-18 2010-08-26 武田薬品工業株式会社 縮合複素環化合物
WO2010119881A1 (ja) * 2009-04-15 2010-10-21 第一三共株式会社 インドリン化合物
JP2010265258A (ja) * 2009-04-15 2010-11-25 Daiichi Sankyo Co Ltd ピリミジルインドリン化合物を含有する医薬組成物
JP2012526097A (ja) * 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
JP2012526096A (ja) * 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519253A (ja) * 2015-04-29 2018-07-19 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ５２に関連する障害の治療または予防に有用なｇｐｒ５２のモジュレーターとしての１−ヘテロアリール−インドリン−４−カルボキサミド

Also Published As

Publication number Publication date
EP2445901A1 (en) 2012-05-02
US20110021491A1 (en) 2011-01-27
TW201113269A (en) 2011-04-16
US8481731B2 (en) 2013-07-09
WO2010149685A1 (en) 2010-12-29
AR077214A1 (es) 2011-08-10

Similar Documents

Publication Publication Date Title
JP2012530758A (ja) 新規化合物、医薬組成物及びそれに関する方法
JP6011543B2 (ja) 糖尿病、肥満および関連疾患の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン
JP5467151B2 (ja) 新規化合物、医薬組成物及びそれに関する方法
CN103958495B (zh) 作为gpr-119的调节剂的化合物
KR101071389B1 (ko) 디펩티딜 펩티다제 억제제
RU2734500C2 (ru) Гетероциклические вещества - агонисты gpr119
EP2780337B1 (en) Substituted cyclopropyl compounds useful as gpr119 agonists
EP4406951A1 (en) Compound as glp-1 receptor agonist and use thereof
WO2010048149A2 (en) Heterocyclic modulators of gpr119 for treatment of disease
JP2010533712A (ja) 抗糖尿病化合物としてのベータカルボリン誘導体
JP6094578B2 (ja) 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
CN103221046A (zh) 作为gpr119调节剂的哌啶基取代的内酰胺
MX2010011070A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2011000392A (es) 4-fenoxi-metil-piperidinas como moduladoras de la actividad de gpr119.
CN1639164A (zh) 含氮杂环化合物
KR20130113352A (ko) 피페리딘 유도체 및 대사 장애의 치료를 위한 이의 용도
MX2010009203A (es) Compuestos y composiciones como modulares de la actividad de gpr119.
JP2007504229A (ja) 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
US9102624B2 (en) Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
TW201326155A (zh) 作為ｇｐｒ１１９調節劑之經哌啶基取代的內醯胺
JP6446433B2 (ja) ピリミジン置換ピロリジン誘導体、医薬組成物及びこれらの使用
EP2771000B1 (en) Substituted piperidinyl compounds useful as gpr119 agonists
JP6136032B2 (ja) 新規な２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン、Ｇタンパク質共役受容体ＧＰＲ１１９のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物
JP2016518420A (ja) ピロリジン誘導体、その医薬組成物及び使用
JP6263789B2 (ja) Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150421